公开(公告)号：WO2014100853A1

公开(公告)日：2014-07-03

申请号：PCT/AU2013/001509

申请日：2013-12-20

Applicant: CELLESTIS LIMITED

Inventor： BOYLE, Jeff ,  KNIGHTS, Ashley ,  MUNIAN, Carmen

IPC: G01N33/53 ,  G01N33/50 ,  C12Q1/68

CPC classification number: G01N33/5091 ,  A61K39/12 ,  A61K39/245 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/16222 ,  G01N33/5047 ,  G01N2333/57

Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen.

Abstract translation: 本公开一般涉及基于免疫学的诊断测定领域，包括测量细胞介导的免疫反应性的测定。 本公开教导了基于细胞介导的具有增强的敏感性的免疫反应性的受试者暴露于抗原的诊断，其通过在样品与抗原孵育期间添加非还原糖来实现。

公开(公告)号：WO2014096803A1

公开(公告)日：2014-06-26

申请号：PCT/GB2013/053320

申请日：2013-12-17

Applicant: IMMUNOCORE LIMITED ,  ADAPTIMMUNE LIMITED

Inventor： CAMERON, Brian John ,  VUIDEPOT, Annelise Brigitte ,  JAKOBSEN, Bent Karsten

IPC: G01N33/68 ,  G01N33/50 ,  C07K14/725

CPC classification number: C40B30/02 ,  G01N33/505 ,  G01N33/6866 ,  G01N33/6878 ,  G01N2333/57 ,  G01N2333/70539 ,  G01N2500/04

Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.

Abstract translation: 本发明提供了一种用于预测与主要组织相容性复合体（MHC）呈递并用于给予受试者的靶肽结合的结合肽是否具有与受试者体内另外的肽交叉反应的潜力的方法。 该方法包括鉴定结合肽所结合的靶肽中的至少一个结合基序的步骤; 并搜索存在于受试者中的包含至少一个结合基序而不是靶肽的肽。 一种或多种这样的肽的存在表明结合肽具有在体内交叉反应的潜力。

公开(公告)号：WO2014004385A2

公开(公告)日：2014-01-03

申请号：PCT/US2013/047353

申请日：2013-06-24

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： WANG-JOHANNING, Feng

IPC: A61K39/12

CPC classification number: A61K39/0011 ,  A61K39/12 ,  A61K2039/585 ,  C12N2740/10034 ,  G01N33/57415 ,  G01N33/57449 ,  G01N2333/15 ,  G01N2333/57 ,  G01N2333/70539

Abstract: The present provides tumor-associated antigens and their use as vaccines for treating and limiting cancers in a patient. In specific aspects, HERV type K envelope proteins and peptides are provided. Such proteins and peptides can be used to elicit specific immune responses - both humoral and cellular - that target tumor cells expressing the HERV type K envelope protein.

Abstract translation: 本发明提供肿瘤相关抗原及其作为疫苗用于治疗和限制患者中的癌症的用途。 在具体方面，提供了HERV型K包膜蛋白和肽。 这样的蛋白质和肽可以用于引发针对表达HERV型K包膜蛋白的肿瘤细胞的特异性免疫应答（体液和细胞）。

公开(公告)号：WO2013168876A1

公开(公告)日：2013-11-14

申请号：PCT/KR2012/011293

申请日：2012-12-21

Applicant: 가톨릭대학교 산학협력단

Inventor： 양철우 ,  조미라 ,  최종영 ,  전주연 ,  김희언 ,  변재경 ,  임예빈 ,  정병하 ,  김경운

IPC: G01N33/53 ,  C12Q1/02

CPC classification number: G01N33/5091 ,  G01N33/56966 ,  G01N33/56972 ,  G01N33/56977 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/57 ,  G01N2800/245

Abstract: 본 발명은 이식 후 면역상태를 모니터링할 수 있는 방법 및 키트에 관한 것으로서, 본 발명에서 제공하는 이식 후 면역상태 모니터링 키트 및 이식 후 개체의 면역상태를 모니터링 하는 방법은 이식 후 개체 내의 면역상태를 손쉽고 정확하게 판단할 수 있어 이식 후 처방되는 면역억제제의 과다 사용을 줄일 수 있는 효과가 있고, 환자 개개인에 대한 면역 상태를 관리할 수 있는 효과가 있다.

Abstract translation: 本发明涉及用于在移植后监测免疫状态的方法和试剂盒。 根据用于监测移植后的免疫状态的试剂盒以及本发明的移植后的个体的免疫状态的监视方法，能够容易且准确地测定移植后的个体的免疫状态，因此， 可以防止移植后规定的免疫抑制剂的过度使用，并且可以管理每个患者的免疫状态。

公开(公告)号：WO2012085652A3

公开(公告)日：2012-11-22

申请号：PCT/IB2011003145

申请日：2011-12-22

Applicant: CT HOSPITALIER UNIVERSITAIRE VAUDOIS ,  PANTALEO GIUSEPPE ,  HARARI ALEXANDRE ,  PERREAU MATTHIEU

Inventor： PANTALEO GIUSEPPE ,  HARARI ALEXANDRE ,  PERREAU MATTHIEU

IPC: C12Q1/68 ,  G01N33/569

CPC classification number: G01N33/5695 ,  G01N33/6863 ,  G01N2333/35 ,  G01N2333/525 ,  G01N2333/55 ,  G01N2333/57

Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T- cells expressing TNF- alpha, IFN- gamma, and IL-2, or by determining expression of IL-17.

Abstract translation: 本公开涉及通过确定表达TNF-α，IFN-γ和IL-2的多功能CD4 + T细胞的百分比或通过测定IL-17的表达来区分具有活性和潜伏性结核病的哺乳动物的方法。

公开(公告)号：WO2012051106A1

公开(公告)日：2012-04-19

申请号：PCT/US2011/055588

申请日：2011-10-10

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  KASPER, Lloyd, H. ,  SMITH, Jacqueline, Y.

Inventor： KASPER, Lloyd, H. ,  SMITH, Jacqueline, Y.

IPC: C07K14/47 ,  A61K38/00 ,  A61P19/08 ,  A61K38/06 ,  A61K38/07

CPC classification number: G01N33/6863 ,  A61K9/0019 ,  A61K31/785 ,  A61K38/02 ,  A61K38/07 ,  C07K14/52 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6896 ,  G01N2333/525 ,  G01N2333/54 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/285 ,  G01N2800/52

Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-a concentration, IL-2 concentration and IFN-γ concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.

Abstract translation: 一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单次临床攻击的方法，其包含含有醋酸格拉司他和药学上可接受的载体的药物组合物，其包括以下步骤：通过评估人受试者是否是醋酸格拉特 生物标志物选自IL-17浓度，TNF-α浓度，IL-2浓度和IFN- 浓度或其组合，并且如果将人类受试者鉴定为乙酸格拉他灵反应者，则将包含乙酸格拉默和药学上可接受的载体的药物组合物给予人受试者。

公开(公告)号：WO2012011144A3

公开(公告)日：2012-04-12

申请号：PCT/IT2011000266

申请日：2011-07-25

Applicant: 4ROMAPEPTIDI S R L ,  MARIANI FRANCESCA ,  AMICOSANTE MASSIMO ,  COLIZZI VITTORIO ,  SALTINI CESARE

Inventor： MARIANI FRANCESCA ,  AMICOSANTE MASSIMO ,  COLIZZI VITTORIO ,  SALTINI CESARE

IPC: A61K38/16 ,  C07K14/35 ,  C07K16/12 ,  C12N5/00 ,  C12Q1/68 ,  G01N33/569

CPC classification number: G01N33/56972 ,  A61K38/10 ,  A61K38/164 ,  C07K7/08 ,  C07K14/35 ,  G01N33/5695 ,  G01N33/6866 ,  G01N2333/35 ,  G01N2333/57

Abstract: The present invention refers to the use of gene sequences or portions thereof characterized in that the same belong to the classes of in vitro and ex vivo induced, repressed or conserved genes in Mycobacterium tuberculosis currently infected human macrophages and to corresponding peptides or consensus peptides or proteins for the preparation of specific bio-markers for the diagnosis and prevention of active or latent disease.

Abstract translation: 本发明涉及基因序列或其部分的用途，其特征在于它们属于目前感染的人巨噬细胞的结核分枝杆菌中的体外和离体诱导，抑制或保守基因类型以及相应的肽或共有肽或蛋白质 用于制备用于诊断和预防活动性或潜伏性疾病的特异性生物标志物。

公开(公告)号：WO2011003905A1

公开(公告)日：2011-01-13

申请号：PCT/EP2010/059635

申请日：2010-07-06

Applicant: TRANSGENE SA ,  ACRES, Bruce ,  GRELLIER, Benoît

Inventor： ACRES, Bruce ,  GRELLIER, Benoît

IPC: G01N33/50 ,  G01N33/574 ,  G01N33/68

CPC classification number: G01N33/6866 ,  A61K38/1738 ,  A61K39/0011 ,  A61K39/285 ,  C12N2710/24111 ,  G01N33/6869 ,  G01N2333/5428 ,  G01N2333/57 ,  G01N2800/52

Abstract: The present invention concerns biomarkers and use thereof for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment.

Abstract translation: 本发明涉及生物标志物及其用途，用于确定受试者是否在这种治疗后是否或不易于发展预防或治疗性免疫应答。

公开(公告)号：WO2009052623A1

公开(公告)日：2009-04-30

申请号：PCT/CA2008/001873

申请日：2008-10-27

Applicant: GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  JONES, Richard, B. ,  OSTROWSKI, Mario, A. ,  NIXON, Douglas, F. ,  NDHLOVU, Lishomwa, C. ,  RINI, James, M.

Inventor： JONES, Richard, B. ,  OSTROWSKI, Mario, A. ,  NIXON, Douglas, F. ,  NDHLOVU, Lishomwa, C. ,  RINI, James, M.

IPC: C07K14/725 ,  A61K38/17 ,  A61K39/21 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  G01N33/53 ,  G01N33/567 ,  G01N33/68 ,  C07K16/28

CPC classification number: C07K16/1009 ,  C07K14/70503 ,  C12N2740/16011 ,  G01N33/56988 ,  G01N33/576 ,  G01N33/6863 ,  G01N33/6866 ,  G01N2333/525 ,  G01N2333/57 ,  G01N2800/52 ,  G01N2800/56

Abstract: The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.

Abstract translation: 本申请涉及通过调节Tim-3活性来治疗慢性病毒感染的方法。 此外，本申请涉及使用Tim-3表达来诊断或监测免疫系统活性或功能，慢性病毒感染和炎性疾病的方法。

公开(公告)号：WO2007147140A3

公开(公告)日：2008-05-08

申请号：PCT/US2007071381

申请日：2007-06-15

Applicant: CYTONICS CORP ,  SCUDERI GAETANO J

Inventor： SCUDERI GAETANO J

IPC: G01N33/48 ,  C12P19/34 ,  G01N33/53

CPC classification number: A61B10/0045 ,  A61B2010/0077 ,  A61K38/1793 ,  G01N33/6863 ,  G01N2333/57 ,  G01N2800/2842

Abstract: The present invention provides methods, reagents and kits for the diagnosis and treatment of spinal-related pain, e.g., radiculopathic pain, facet pain and discogenic pain. Cytokine biomarkers, e.g., IFNy can be used to diagnose spine-related injury. It is also a finding of the present invention that spinal-related pain can be alleviated by administering therapeutic agents to the site of diagnostic presence of the cytokine biomarker. This invention further provides methods for extraction of samples from the spine, e.g., disc space samples, epidural samples and facet joint samples.

Abstract translation: 本发明提供了用于诊断和治疗脊柱相关疼痛的方法，试剂和试剂盒，例如脊神经痛，面部疼痛和椎间盘疼痛。 细胞因子生物标志物，例如IFNγ可用于诊断脊柱相关损伤。 也是本发明的发现，通过将治疗剂施用于细胞因子生物标志物的诊断性存在位点可以减轻脊髓相关疼痛。 本发明还提供了用于从脊柱提取样品的方法，例如圆盘空间样品，硬膜外样品和小关节样品。